Want to join the conversation?
$ENTA announced data showing patients with genotype 1 chronic HCV infection who received recommended regimen of $ABBV's VIEKIRAX EXVIERA achieved high sustained virologic response rates at 48 weeks post-treatment. $ENTA's lead protease inhibitor, Paritaprevir, is one of the direct-acting antivirals in the VIEKIRAX EXVIERA treatment regimen.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)